Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3521-3530 Newer>

Pharmaceutical Executive March 1, 2007 Kim D. Slocum	Opinion: Trigger Points Timing is everything. But when is it right? As pharma begins to confront the looming issue of sales-force downsizing, execs should keep an eye on six factors that can help answer that very question.
Pharmaceutical Executive March 1, 2007	Direct to Consumer: Q&A with Mark Spellman and Loreen Babcock Unit 7's Mark Spellman and Loreen Babcock say when it comes to using emotion in advertising, fear plus hope is the most effective formula.
Pharmaceutical Executive March 1, 2007 George Koroneos	Marketing to Professionals: The Formulary Rebound Marketers' professional strategies often fall on deaf ears when there is a cheap alternative available. Here are some tactics that make your brand heard.
Pharmaceutical Executive March 1, 2007 Alex Porter	Alternative Media: Search-Engine Marketing: Click, Click ... Are You There? Pharma marketers turn to pay-per-click advertising to boost their product's reach.
Pharmaceutical Executive March 1, 2007 Jeffrey Zornitsky	Sales Management: Get Committed By better managing relationships with physicians, pharma companies can develop a base of dedicated prescribers.
Pharmaceutical Executive March 1, 2007 Maraldo & Lister	Back Page: Let's Get Gutsy Pharma gets no respect from the public. But instead of complaining about it, industry should stop whining and start leading. Here's a seven-point starter kit.
Pharmaceutical Executive March 1, 2007	Finance: Q&A with Annette Grimaldi It's now more lucrative for a small pharmaceutical company to sell than to go public. Here is how the past year has shaped up - and what might be next on the horizon.
Reason March 2007 Kerry Howley	Who Owns Your Body Parts? In the U.S., demand for human tissue has never been higher, and human remains have never been more valuable. Everyone's making money in the market for body tissue -- except the donors.
The Motley Fool March 6, 2007 Brian Lawler	InterMune Swoons Shares of InterMune fall after it announces negative clinical trial results for one of its drugs.
The Motley Fool March 5, 2007 Rich Smith	ViaCell Not Doing Well The company's biotech half continues to sap revenue from the moneymaking side. Investors, take note.
<Older 3521-3530 Newer> Return to current articles.